Isosorbide Dinitrate

Introduction Overview

Generic Name

isosorbide dinitrate

Brand Name

Isochron, Isordil Titradose, Sorbitrate, Dilatrate-SR, Isordil, ISDN, Isordil Tembids

Dosage Form

oral tablet (5 mg, 10 mg, 20 mg, 30 mg, 40 mg), extended-release oral tablet (40 mg)

Drug Class

Antianginal agents

Pharmacokinetics

Absorption: Isosorbide dinitrate is rapidly absorbed from the gastrointestinal tract with an oral bioavailability affected by significant first-pass hepatic metabolism. Peak plasma concentrations are usually achieved within 1–2 hours after administration of immediate-release formulations, while extended-release forms provide a sustained plasma concentration over longer periods. Food intake may slightly delay absorption but does not significantly affect systemic availability. Sublingual administration bypasses first-pass metabolism, allowing rapid onset for acute angina treatment. Variability in individual patient metabolism and hepatic blood flow can influence absorption rates clinically.

Distribution: After absorption, isosorbide dinitrate is widely distributed throughout the body with a moderate volume of distribution, reflecting distribution into body fluids and tissues. The drug is minimally bound to plasma proteins, facilitating its rapid tissue diffusion. It readily crosses biological membranes, including vascular tissues where it exerts its pharmacodynamic effects. The half-life of distribution typically ranges from a few minutes to hours depending on the formulation and dosing regimen.

Metabolism: Isosorbide dinitrate undergoes extensive hepatic metabolism primarily via denitration and reduction pathways, resulting in several metabolites, including isosorbide-5-mononitrate and isosorbide-2-mononitrate, which retain pharmacologic activity. The hepatic enzymes responsible include cytochrome P450 isoforms and other nitro-reductase enzymes. Metabolic clearance varies among individuals and may be influenced by hepatic function, concomitant medications, and genetic factors. The active metabolites contribute to the prolonged therapeutic effect, especially with extended-release formulations.

Elimination: The drug and its metabolites are primarily eliminated renally. Approximately 60-70% of the administered dose is excreted in the urine within 24 hours, mostly as metabolites. The elimination half-life ranges from 1 to 4 hours for isosorbide dinitrate and varies with the metabolite. Renal impairment can alter elimination and prolong the half-life, necessitating close monitoring. Fecal excretion is minimal. The clinical importance of the elimination pathway underscores the need to adjust dosing in renal dysfunction and monitor for accumulation.

Dosage Forms

Available Dosage Forms: Isosorbide dinitrate is available as oral immediate-release tablets in dosages of 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg. Extended-release oral tablets are available primarily in 40 mg doses to provide sustained drug plasma levels for long-term angina prophylaxis. Both types of dosage forms are designed to accommodate different clinical needs: immediate relief in acute angina attacks and chronic angina prevention.

Dosages for Adults and Adolescents: The dosing regimen varies according to the formulation and clinical indication. Immediate-release tablets are typically dosed multiple times daily, often two to four times, considering the short plasma half-life and the need to prevent tolerance development via nitrate-free intervals. Standard dosing for adults may start at 5–20 mg two to three times per day, titrated based on therapeutic response and side effect profile. Extended-release tablets are dosed less frequently, usually once or twice daily (e.g., 40 mg every 12 hours), to maintain stable plasma concentrations and improve adherence. Adjustments are made by the physician depending on symptom control and tolerability.

Specific Patient Populations: In patients with hepatic or renal impairment, dosage adjustments may be necessary due to altered metabolism and elimination. Elderly patients generally require cautious dose titration to minimize hypotension and dizziness risk. Pediatric use is less well established and generally off-label; dosing should be individualized under specialist supervision. Pregnancy and lactation considerations require risk-benefit evaluation due to limited data on safety.

Formulation Details: Immediate-release tablets (5 mg; 10 mg; 20 mg; 30 mg; 40 mg) are intended for fast onset action, suitable for preventing anginal episodes at regular intervals but not for acute attack treatment. Extended-release tablets (40 mg) provide sustained plasma levels to prevent angina over longer durations and improve patient compliance while minimizing peak-trough fluctuations. Crushing, chewing, or breaking extended-release tablets is contraindicated as it disrupts the release mechanism and may lead to overdose or subtherapeutic dosing.

Mechanism Of Action

Isosorbide dinitrate is a nitrate vasodilator that acts primarily through the release of nitric oxide (NO) upon biotransformation in vascular smooth muscle cells. This NO activates soluble guanylate cyclase, increasing intracellular cyclic guanosine monophosphate (cGMP) levels, which leads to a cascade of intracellular events resulting in smooth muscle relaxation. This vasodilation predominantly affects veins more than arteries, reducing preload by venous pooling and lowering myocardial oxygen demand.

At the cellular level, isosorbide dinitrate-derived NO stimulates protein kinase G, which phosphorylates several target proteins leading to decreased intracellular calcium concentration and desensitization of the contractile apparatus to calcium. This biochemical mechanism relaxes vascular smooth muscle cells and leads to dilatation of large capacitance vessels and coronary arteries, improving myocardial oxygen delivery.

Clinically, the reduction in ventricular preload decreases left ventricular end-diastolic pressure and myocardial wall tension, alleviating the workload on the heart and reducing ischemia. Additionally, coronary artery dilation helps improve collateral blood flow in ischemic myocardium. The drug does not significantly reduce systemic arterial pressure but optimally balances oxygen supply and demand in cardiac tissue.

Comparatively, isosorbide dinitrate is metabolized to active mononitrate metabolites that provide prolonged nitrate effects versus other nitrates like nitroglycerin that have shorter duration of action. Several clinical trials have demonstrated its efficacy in both acute angina prophylaxis and chronic management, highlighting the importance of tailored dosing and nitrate-free intervals to prevent tolerance development.

Pharmacological Actions

Potent vasodilator action primarily on venous capacitance vessels, leading to decreased preload.
Coronary artery dilation improving myocardial oxygen supply and collateral circulation.
Reduction of left ventricular end-diastolic pressure and myocardial wall stress.
Increased intracellular cyclic GMP via nitric oxide release causing smooth muscle relaxation.
Metabolism to active isosorbide mononitrate metabolites with sustained antianginal effects.
Decreases myocardial oxygen consumption by reducing cardiac workload.
Minimal effects on systemic arterial resistance but significant preload reduction.
Rapid onset of action with immediate-release tablets; sustained plasma levels with extended-release forms.
Ability to relieve and prevent episodes of angina pectoris triggered by exertion or stress.
Tolerance development potential requiring nitrate-free interval dosing strategies.
Improvement of exercise tolerance and delay of onset of angina symptoms.
Reduction in frequency and severity of anginal attacks with prolonged use.
No significant negative inotropic effect, suitable for use in patients with preserved ventricular function.
Hemodynamic effects beneficial in congestive heart failure as adjunct therapy.
Exerts direct smooth muscle relaxation impacting esophageal and peripheral vascular beds in some cases.

Therapeutic Or Clinical Uses

Prevention of angina pectoris caused by coronary artery disease.
Treatment of chronic stable angina to reduce frequency and severity of attacks.
Prophylactic management of variant (Prinzmetal's) angina via coronary vasodilation.
Adjunct therapy in congestive heart failure to reduce myocardial oxygen demand.
Used in combination regimens for ischemic heart disease management.
Management of esophageal spasm unresponsive to other therapies.
Prevention of angina attacks triggered by physical exertion or emotional stress.
Alternative nitrate therapy for patients intolerant to nitroglycerin.
Part of treatment plans in patients with pulmonary hypertension in select cases.
Prophylaxis during high-risk cardiac procedures or stress to reduce ischemic episodes.
Off-label uses include management of certain vascular spastic disorders.
Improvement of exercise capacity in ischemic heart disease patients.
Treatment strategy in patients with refractory angina when revascularization is not feasible.
Reduction of left ventricular filling pressures in symptomatic heart failure patients.
Supportive therapy during acute coronary syndrome in combination with other agents.

Side Or Adverse Effects

Severe headaches due to cerebral vasodilation, often diminishing with continued use.
Flushing characterized by warmth, redness, and a tingling sensation.
Hypotension causing light-headedness, dizziness, or fainting especially on standing.
Tachycardia including palpitation, pounding heartbeat, or chest fluttering sensations.
Worsening angina or chest pain as a paradoxical effect in some cases.
Nausea, vomiting, or gastrointestinal discomfort occasionally reported.
Rare allergic reactions manifesting as hives, facial swelling, or difficulty breathing.
Tolerance development resulting in decreased efficacy with continuous use.
Syncope secondary to profound vasodilation and blood pressure reduction.
Flushing and hypotension exacerbated by concurrent alcohol use.
Rare reports of vision disturbances and confusion during overdose.
Exacerbation of hypotension with concomitant use of other antihypertensives.
Rare electrolyte disturbances may occur secondary to prolonged vasodilation and volume changes.
Sudden severe headache or neurological symptoms warrant immediate assessment.
Local irritation or discomfort with sublingual administration in formulations used.

Precautions

Use cautiously in patients with congestive heart failure due to preload dependence.
Monitor blood pressure regularly to avoid symptomatic hypotension.
Avoid abrupt discontinuation to prevent rebound angina or ischemic events.
Use with caution in renal impairment due to altered drug clearance.
Evaluate hepatic function periodically in prolonged therapy because of hepatic metabolism.
Implement nitrate-free intervals to reduce tolerance development risk.
Avoid use in patients with known hypersensitivity to nitrates or nitrate derivatives.
Adjust dosing carefully in elderly patients sensitive to hypotensive effects.
Use caution in patients with low baseline blood pressure or volume depletion.
Avoid concomitant use with phosphodiesterase inhibitors due to severe hypotension risk.
Warn patients to avoid activities requiring alertness if dizziness or lightheadedness occurs.
Educate patients on recognizing signs of overdose and to seek urgent care if needed.
Avoid use during acute myocardial infarction without careful medical supervision.
Monitor electrolytes and volume status in patients with prolonged illness or diarrhea.
Advise women who are pregnant or breastfeeding to consult healthcare providers before use.

Warnings

Do not use in combination with phosphodiesterase type 5 inhibitors (e.g., sildenafil, tadalafil) due to risk of life-threatening hypotension.
Seek immediate medical attention if symptoms of a heart attack occur despite medication use.
Use is contraindicated if patient exhibits early signs of myocardial infarction (chest pain with radiating discomfort, nausea, sweating).
Careful monitoring is required to prevent profound hypotension and syncope especially in initial dose titration.
Risk of severe headache may necessitate symptomatic treatment but should not lead to abrupt cessation.
Avoid overdose; excessive use can cause fatal outcomes including seizures and circulatory collapse.
Be aware of potential for drug tolerance necessitating intermittent dosing.
Abrupt discontinuation can provoke severe angina or myocardial ischemia.
Use caution in patients with concurrent hypotensive states or on other vasodilators.
Ensure patients understand the importance of not crushing or breaking extended-release tablets.
Risk of interaction with other antihypertensive drugs can exacerbate hypotension.
Not recommended in patients with orthostatic hypotension without close supervision.
Avoid use in patients allergic to nitrates or with cardiogenic shock.
Ensure adequate patient education on avoiding overuse or misapplication of sublingual forms.
Monitor for signs of paradoxical worsening of angina and seek prompt intervention.

Contraindication

Known hypersensitivity to isosorbide dinitrate, isosorbide mononitrate, or other nitrates.
Concurrent use with erectile dysfunction medications such as sildenafil, tadalafil, vardenafil, avanafil.
Acute myocardial infarction with hypotension or shock.
Severe anemia due to risk of worsening myocardial oxygen supply.
Increased intracranial pressure or head trauma where vasodilation may be harmful.
Constrictive pericarditis or cardiac tamponade where preload reduction is detrimental.
Severe hypotension or hypovolemia where further vasodilation is unsafe.
Use in patients with early signs or ongoing myocardial infarction without medical supervision.
Known intolerance or allergy history to nitrate compounds.
Use in patients taking nitric oxide donors or other organic nitrates for angina.
Severe hepatic or renal impairment if benefit-risk ratio is unfavorable.
Severe aortic stenosis or hypertrophic obstructive cardiomyopathy due to preload dependence.
Concomitant use with riociguat (Adempas) due to additive hypotensive effects.
Use in patients with glaucoma requiring caution due to potential pressure changes.
Known hypersensitivity to inactive ingredients in formulation.

Drug Interactions

Concomitant use with phosphodiesterase inhibitors (sildenafil, tadalafil, vardenafil, avanafil) can cause profound hypotension and cardiovascular collapse.
Additive hypotensive effects when combined with other vasodilators or antihypertensives such as calcium channel blockers or beta-blockers.
Interaction with diuretics may potentiate blood pressure lowering and risk of dehydration.
Potential enhanced hypotensive effect with alcohol consumption.
May increase the effects of other nitrates or nitric oxide donors leading to overdose risks.
Interaction with riociguat can cause severe hypotension – combination contraindicated.
Co-administration with antihypertensive agents requires careful monitoring for signs of excessive blood pressure reduction.
Possible altered metabolism or clearance when used with hepatic enzyme inducers or inhibitors.
Increased risk of dizziness or fainting when used with sedatives or CNS depressants.
Careful monitoring needed when combined with anticoagulants due to possible additive bleeding risk.
Interactions with lithium have been reported, necessitating monitoring of lithium levels.
Combination with medications causing electrolyte imbalance may complicate therapy.
May affect the pharmacodynamics of beta-agonists or antagonists used in cardiac therapy.
Herbal supplements such as ginseng or garlic may potentiate nitrate effects, increasing hypotensive risk.
Over-the-counter cold or allergy medications containing sympathomimetics may alter hemodynamic responses.

Preparations Of The Drug

Immediate-release oral tablets: 5 mg, 10 mg, 20 mg, 30 mg, 40 mg dosages for acute and prophylactic angina management.
Extended-release oral tablets: 40 mg formulation designed for sustained plasma concentrations and once or twice daily dosing.
Sublingual preparations are recommended for rapid relief of acute anginal attacks (though specific sublingual isosorbide dinitrate formulations are less commonly used; alternate nitrates like nitroglycerin are preferred).
Combination formulations with hydralazine are available for heart failure management under specialized clinical protocols (not covered in this monograph).
Tablets should be stored at room temperature, protected from moisture, heat, and light, and kept in tightly closed containers.
Available as branded and generic formulations, allowing flexibility in prescribing and cost management.
Manufactured in both film-coated immediate-release and extended-release tablet forms to optimize therapeutic profiles.
No oral liquid formulations commonly available; oral tablets remain standard dosage form.
Various branded preparations may differ in excipients and bioavailability; switching formulations may require dose adjustments.
Packaging includes bottles or blister packs with clear labeling instructing proper use and dosing intervals.
Patient information leaflets accompanying preparations provide usage, storage, and safety information to enhance adherence.
Manufacturers provide comprehensive prescribing information including warnings, contraindications, and pharmacokinetic data.
Extended-release preparations are specifically formulated to avoid dose dumping and ensure controlled release.
Some formulations are enteric-coated to protect the drug from degradation in acidic gastric environment, enhancing absorption.
Regular updates to product formulations reflect advances in drug delivery technology and clinical feedback.